Scott Kathleen D. sold $13 of DRMA
Scott Kathleen D. sold 11 shares of Dermata Therapeutics, Inc. (DRMA) at $1.19 on 2026-06-16.
How this was made
The 30-second read
Why it matters
The disclosure updates insider ownership/behavior but does not provide new company fundamentals (no clinical, regulatory, or financial guidance changes).
Market read
Traders may monitor for follow-on insider activity, but the disclosed transaction is small and lacks a fundamental catalyst.
What to watch
The article provides only the sale size and price; it does not include broader insider activity trends, option exercises, or subsequent purchases.
Background
The article is an SEC Form 4 insider transaction disclosure for Dermata Therapeutics, Inc.
Ticker impact
Dermata Therapeutics director Scott Kathleen D. sold 11 shares in an open-market transaction at $1.1901/share, leaving 0 shares.
Low likelihood of a sustained price move; any impact would be short-lived unless followed by larger insider activity.
The filing is a routine, small-size insider sale with no 10b5-1 plan and no accompanying operational/regulatory catalyst in the text.
Market effects
No sector read-across; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
A small, non-10b5-1 sale can be driven by personal liquidity needs and may not reflect company outlook.
Key entities
- issuerDermata Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderScott Kathleen D.
Director who sold 11 shares on 2026-06-16.
